Online inquiry

IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5109MR)

This product GTTS-WQ5109MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD52 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001803.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1043
UniProt ID P31358
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5109MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12437MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ10495MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ11755MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ3381MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ9708MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ7210MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ15223MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ2275MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALXN1007
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW